15 December 2016 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Background: Although the anti-HIV-1 effects of vitamin D (VitD) have been reported, mechanisms behind such protection remain largely unexplored. Methods: The effects of two precursor forms (cholecalciferol/calciol at 0.01, 1 and 100 nM and calcidiol at 100 and 250 nM) on HIV-1 infection, immune activation, and gene expression were analyzed in vitro in cells of Colombian and Italian healthy donors. We quantified levels of released p24 by enzyme-linked immunosorbent assay, of intracellular p24 and cell-surface expression of CD38 and HLA-DR by flow cytometry, and mRNA expression of antiviral and immunoregulatory genes by real-time reverse transcription-polymerase chain reaction. Results: Cholecalciferol decreased the frequency of HIV-1-infected p24+CD4+ T cells and levels of p24 in supernatants in a dose-dependent manner. Moreover, the CD4+CD38+HLA-DR+ and CD4+CD38−HLA-DR+ subpopulations were more susceptible to infection but displayed the greatest cholecalciferol-induced decreases in infection rate by an X4-tropic strain. Likewise, cholecalciferol at its highest concentration decreased the frequency of CD38−HLA-DR+ but not of CD38+HLA-DR+ T-cell subsets. Analyzing the effects of calcidiol, the main VitD source for immune cells and an R5-tropic strain as the most frequently transmitted virus, a reduction in HIV-1 productive infection was also observed. In addition, an increase in mRNA expression of APOBEC3G and PI3 and a reduction of TRIM22 and CCR5 expression, this latter positively correlated with p24 levels, was noted. Conclusions: VitD reduces HIV-1 infection in T cells possibly by inducing antiviral gene expression, reducing the viral co-receptor CCR5 and, at least at the highest cholecalciferol concentration, by promoting an HIV-1-restrictive CD38+HLA-DR− immunophenotype.
1 March 2019 in Applied and Environmental Microbiology
Wolbachiastrains are common endosymbionts in insects, with multiple strains often coexisting in the same species. The coexistence of multiple strains is poorly understood but may rely onWolbachiaorganisms having diverse phenotypic effects on their hosts. AsWolbachiais increasingly being developed as a tool to control disease transmission and suppress pest populations, it is important to understand the ways in which multipleWolbachiastrains persist in natural populations and how these might then be manipulated. We have therefore investigated viral protection and the molecular basis of cytoplasmic incompatibility in two coexistingWolbachiastrains with contrasting effects on host reproduction.
14 July 2016 in Hormone Molecular Biology and Clinical Investigation
Objective: Vitamin D (VitD) is an anti-inflammatory hormone; however, some evidence shows that VitD may induce the expression of activation markers, such as CD38 and HLA-DR. We explored its effect on the expression of these markers on CD4 + and CD8 + T-cells in vitro, and their potential correlations in vivo. Materials and methods: CD38 and HLA-DR expression was measured by flow cytometry in PHA/IL-2-activated mononuclear cells cultured under VitD precursors: three cholecalciferol (10 −11 M, 10 −9 M, 10 −7 M; n=11) and two calcidiol (40 ng/mL, 80 ng/mL; n=9) concentrations. The correlation between the expression of these markers in freshly isolated blood cells and serum levels of calcidiol was also explored (n=10). Results: Cholecalciferol at 10 −7 M increased the proportion of CD4 + CD38 + and CD8 + CD38 + cells, and decreased CD8 + HLA-DR + cells. As co-expression, it increased the CD38 + HLA-DR − and decreased CD38 − HLA-DR + subpopulations in both CD4 + and CD8 + T-cells, and decreased CD4 + CD38 − HLA-DR − and CD8 + CD38 + HLA-DR + ; whereas both calcidiol concentrations decreased the proliferation of CD38 − HLA-DR − and CD38 − HLA-DR + subpopulations. Both forms of VitD increased the number of CD38 molecules per cell. In contrast, there was a positive but non-significant correlation between serum calcidiol levels and the expression of CD38 and HLA-DR in CD4 + and CD8 + T-cells. Conclusion: Although no significant correlations were observed in vivo in healthy subjects, VitD treatment in vitro modulated immune activation by increasing the expression of CD38 and decreasing the proliferation of HLA-DR + and resting cells, which may correlate with improved effector and decreased proliferative capabilities. These results highlight the potential use of VitD as therapeutic strategy in immune disorders.